Form 4: Provectus CEO Edward Pershing Acquires Convertible Note

CEO Edward Pershing acquired a $15,000 8% unsecured convertible promissory note in Provectus Biopharmaceuticals.

Summary

• CEO Edward Pershing acquired a $15,000 8% unsecured convertible promissory note on May 28, 2026.
• The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note matures on May 28, 2027, at which point it automatically converts if not converted earlier.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive signal, as insider investment typically reflects management's belief in the company's long-term viability, though it remains a small transaction relative to corporate scale.

Positives

• Insider participation in company financing demonstrates management confidence in the issuer's future.

Negatives

• The issuance of convertible debt instruments can lead to future dilution of existing common shareholders.

Risks

• Potential dilution of common stock upon conversion of the Series D-1 Preferred Stock.
• Financial obligation to repay or convert the 8% interest-bearing note.

Future Outlook

The note will automatically convert into Series D-1 Preferred Stock on May 28, 2027, which subsequently converts into common stock by December 31, 2028.

Management Comments

• The transaction was executed as part of the Issuer's 2025 Financing.

Industry Context

StockSavvy.ai notes that insider participation in small-cap biotech financing rounds is a common mechanism to signal commitment during capital-intensive clinical development phases.

Comparison to Industry Standards

• Insider debt participation is consistent with standard practices for micro-cap biotech companies seeking to maintain liquidity without immediate equity dilution.
• The use of convertible notes with automatic conversion triggers is a standard financing structure for early-stage pharmaceutical firms.

Related Party Transactions

• The reporting person is the CEO and a Director of the issuer, making this a related party transaction.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual conversion of the note into preferred and subsequently common stock.

Next Steps

• Automatic conversion of the note on May 28, 2027.
• Potential conversion of Series D-1 Preferred Stock into common stock by December 31, 2028.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Insider Trading, Convertible Note, Biotech, Form 4